Originally written 2021; updated 2026 for archival reference. SARS-CoV-2 endemic public-health context now applies. The interpretive framework below — pre-test probability, NAAT vs antigen trade-offs, Ct caveats, viral shedding kinetics — remains the working clinical model used by U.S. reference laboratories.
A COVID-19 result is never just "positive" or "negative" — it is the product of which assay was run, when the swab was collected relative to symptom onset, and the patient's pre-test probability. RT-PCR remains the gold-standard NAAT; LAMP delivers similar sensitivity at point-of-care speed; rapid antigen tests are most useful in the symptomatic days 1–7 and during high-prevalence outbreaks. Ct values are platform-dependent and should not be read as quantitative viral load.
Key Facts
- RT-PCR and LAMP are both NAATs — they detect viral RNA. Antigen tests detect nucleocapsid protein.
- NAAT sensitivity ≈ 95–99%, specificity ≈ 99% in symptomatic patients; antigen sensitivity ranges 40–80% depending on viral load.
- Viral RNA peaks day 3–7 after symptom onset; sensitivity is lowest in the first 1–3 days of infection.
- Ct values are not viral loads — they are platform-, primer-, and sample-dependent.
- Pre-test probability matters — Bayes' theorem dictates that the same result means different things in different patients.
- LAMP runs isothermally at ~65 °C and returns a result in 15–30 minutes from extracted RNA.
The three assay classes
SARS-CoV-2 diagnostic testing falls into three broad assay classes. Knowing which class generated a result is the first step in interpreting it.
RT-PCR (reverse-transcription polymerase chain reaction)
RT-PCR is the reference standard. The assay reverse-transcribes viral RNA into cDNA and amplifies a SARS-CoV-2-specific target (commonly N1, N2, E, or ORF1ab) through 35–45 thermal cycles. Analytical limits of detection are typically 100–1,000 copies/mL. Clinical sensitivity in symptomatic patients is reported between 95% and 99%, with specificity at or above 99%. Turnaround time depends on logistics — instrumentation runs in 60–90 minutes, but reference-lab pipelines historically deliver in 6–24 hours.
LAMP (loop-mediated isothermal amplification)
LAMP amplifies nucleic acid at a single temperature (~65 °C) using a polymerase with strand-displacement activity and 4–6 primers that target distinct regions of the genome. The redundancy of LAMP's primer set gives it specificity comparable to RT-PCR, while the isothermal chemistry eliminates the need for a thermal cycler — making it well suited to point-of-care and decentralized deployment. End-to-end runs on platforms like the OptiGene Genie III/HT complete in 15–30 minutes from extracted RNA.
biotech Point-of-care NAAT OptiGene Genie® LAMP — COVID-19 molecular testing platform Isothermal RT-LAMP with 15–30 min run time. Pairs with Pro-Mag and Pro-Spin extraction chemistries on the Mag Pro-32 instrument for a complete decentralized workflow. arrow_forwardAntigen tests
Lateral-flow antigen tests detect SARS-CoV-2 nucleocapsid protein directly, with no amplification step. Results return in 15–20 minutes. Sensitivity is the dominant trade-off: under symptomatic conditions with high viral load, sensitivity is generally 75–85%; in asymptomatic surveillance it can fall to 35–50%. Specificity stays high (97–99%), which means false positives are uncommon but false negatives are not.
Sensitivity, specificity, and pre-test probability
The post-test probability of disease is the product of pre-test probability and the test's likelihood ratios — that is the formal statement of Bayes' theorem. In plain language: who you tested matters as much as what test you ran.
Consider two patients. A symptomatic adult with a household exposure and consistent symptoms has a pre-test probability of perhaps 60–70%. A negative rapid antigen with ~70% sensitivity moves that probability only modestly — confirmatory NAAT is warranted. The same negative antigen in an asymptomatic person screened in a low-prevalence setting moves the probability close to zero, and no confirmation is needed.
The corollary holds on the positive side. A positive antigen during a hospital surveillance sweep with 0.5% prevalence carries a substantial false-positive risk; a positive antigen during an outbreak with 15% household prevalence is nearly always a true positive. Same test, same result — different meaning.
What a Ct value does and does not tell you
The cycle threshold (Ct) is the number of PCR cycles needed for the fluorescent signal of an amplified target to cross detection. Low Ct (15–25) implies high template input — a heavily replicating patient. High Ct (33–40) implies very low template, near the limit of detection. It is tempting to read Ct as a viral load, but it is not:
- Ct depends on the platform, primer set, master mix, and extraction chemistry. A Ct of 28 on one instrument is not the same biological load as a Ct of 28 on another.
- Sample quality matters. A shallow swab dilutes the input; a high Ct may simply reflect collection technique, not patient biology.
- Late RNA can persist after infectiousness has resolved. A Ct in the high 30s in a recovered patient at day 14 often represents residual non-viable RNA fragments, not replicating virus.
Used carefully — same platform, trended over time, paired with symptom timeline — Ct can support clinical decisions. Used as a single number out of context, it misleads.
False negatives and the viral shedding timeline
The most common cause of a false-negative SARS-CoV-2 test is sampling too early. Viral RNA in the upper respiratory tract is detectable approximately 1–3 days after exposure, peaks around day 3–7 after symptom onset, and declines through day 10–14. A swab taken during the first 24 hours of exposure can easily be negative on the most sensitive NAAT — the virus simply has not replicated to detectable load yet.
Other contributors include shallow anterior-nares collection (vs nasopharyngeal), prolonged transit at ambient temperature without proper preservative, antigen testing during the asymptomatic incubation window, and post-day-14 testing in resolving disease. The clinical implication is that one negative in a symptomatic patient with a strong exposure history is not the end of the workup — repeat NAAT 24–48 hours later.
Symptomatic vs surveillance testing — different goals, different tools
Symptomatic (diagnostic) testing prioritizes sensitivity: the goal is to confirm or rule out infection in a patient already symptomatic. NAATs (RT-PCR or LAMP) are the appropriate first-line tools. Time-to-result also matters when isolation, treatment, or admission decisions hinge on the result, which is where decentralized LAMP platforms compete with reference-lab RT-PCR.
Surveillance testing has a different brief: screen asymptomatic populations to detect outbreaks early. Specificity, throughput, and cost dominate; the lower per-test sensitivity of antigen assays is offset by serial sampling — testing the same person every 48–72 hours catches most infections within the contagious window even with imperfect single-test sensitivity. The serial-sampling mathematics is why antigen testing was effective in nursing-home and school programs despite its sensitivity gap.
Putting it together at the bench
For the practicing laboratory, three working rules emerge from the post-pandemic literature:
- Choose the assay to match pre-test probability. NAAT for symptomatic diagnostic testing; antigen for serial surveillance; never the other way around.
- Document sample timing and quality. Date and time of symptom onset, swab depth, and transport conditions all change the meaning of the result.
- Treat Ct as a hint, not a verdict. If Ct is being used to support a clinical decision, anchor it to a single platform and a trended pattern, not a single number.
Frequently Asked Questions
What is the difference between RT-PCR, LAMP, and antigen tests?
RT-PCR and LAMP are both nucleic acid amplification tests (NAATs) that detect SARS-CoV-2 RNA. RT-PCR uses thermal cycling and typically returns results in 1–6 hours from a reference lab; LAMP runs at a single temperature and produces a result in 15–30 minutes. Antigen tests detect viral nucleocapsid protein, return a result in 15–20 minutes, but have lower analytical sensitivity than NAATs and are most reliable when viral load is high during symptomatic days 1–7.
What does the Ct value on an RT-PCR report mean?
The cycle threshold (Ct) value is the number of PCR cycles required for the target signal to cross detection. A low Ct (e.g., 15–25) indicates high viral RNA load; a high Ct (e.g., 33–40) indicates very low RNA load near the limit of detection. Ct is platform-dependent and is not a quantitative viral-load measurement, but trended Ct values can support clinical interpretation in some settings.
Why can a COVID-19 test be falsely negative?
False negatives most often occur in the first 1–3 days after exposure (before viral replication peaks), with poor sample collection (shallow nasal swab), with antigen tests during the asymptomatic incubation window, or with degraded samples from improper transport. Sensitivity is highest 3–7 days after symptom onset and drops again after day 10–14 as viral shedding declines.
How does pre-test probability change interpretation?
Bayes' theorem governs test interpretation: the post-test probability of disease depends on the prevalence and exposure history of that patient, not the test alone. A symptomatic patient with a known household exposure has a high pre-test probability — a negative antigen result should be repeated by NAAT. A surveillance-screened asymptomatic person in a low-prevalence setting has a low pre-test probability — a positive antigen result should be confirmed by NAAT before isolation decisions.
What is the difference between symptomatic and surveillance testing?
Symptomatic (diagnostic) testing is used to confirm or rule out SARS-CoV-2 in a patient with consistent signs; sensitivity is the priority, so NAATs are preferred. Surveillance testing screens asymptomatic populations to detect outbreaks early — specificity and throughput are the priorities, and serial antigen testing is often acceptable because repeated sampling compensates for single-test sensitivity gaps.
For more information about Pro-Lab Diagnostics' molecular workflow — including the OptiGene Genie® LAMP platform, Pro-Mag magnetic-bead and Pro-Spin silica-column RNA extraction, and the Mag Pro-32 automated extraction instrument — contact info@pro-lab.us or book a call with our scientific team.